Relapse and Metastasis of Atypical Teratoid/Rhabdoid Tumor in a Boy with Neurofibromatosis Type 1 Treated with Recombinant Human Growth Hormone

Abstract

Even though no increased recurrence rate seems to be reported in patients with brain tumors receiving recombinant human growth hormone (rhGH) replacement, in some patients multiple risk factors could put at higher risk for recurrence. In such cases, the decision to start rhGH therapy should be very cautious. A boy with neurofibromatosis type 1 developed an atypical teratoid/rhabdoid tumor (AT/RT) of right cerebellum, treated with surgery, radiotherapy, and chemotherapy. After 3 years of remission, he started rhGH for growth hormone deficiency, having a negative magnetic resonance imaging (MRI) scan. Ten weeks after starting therapy, the boy became symptomatic and MRI showed relapse of AT/RT in the right cerebellum and a new lesion in the brainstem. The boy died of progressive disease. In this case, the connection between AT/RT recurrence and the beginning of rhGH therapy, with a negative pretreatment MRI, cannot be excluded. Additional caution should be used for rhGH in patients with multiple risk factors.

Keywords

NF1 - AT/RT - recurrence - brain tumor - rhGH

• References

• 1 Clayton PE, Banerjee I, Murray PG, Renehan AG. Growth hormone, the insulin-like growth factor axis, insulin and cancer risk. Nat Rev Endocrinol 2011; 7 (1) 11-24
• 2 Darendeliler F, Karagiannis G, Wilton P, Ranke MB, Albertsson-Wikland K, Anthony Price D. On Behalf of the Kigs International Board. Recurrence of brain tumours in patients treated with growth hormone: analysis of KIGS (Pfizer International Growth Database). Acta Paediatr 2006; 95 (10) 1284-1290
• 3 Lefkowitz IB, Rorke LB, Packer RJ. Atypical teratoid tumor of infancy: definition of an entity. Ann Neurol 1987; 22: 448-449
• 4 Packer RJ, Biegel JA, Blaney S , et al. Atypical teratoid/rhabdoid tumor of the central nervous system: report on workshop. J Pediatr Hematol Oncol 2002; 24 (5) 337-342
• 5 Hilden JM, Meerbaum S, Burger P , et al. Central nervous system atypical teratoid/rhabdoid tumor: results of therapy in children enrolled in a registry. J Clin Oncol 2004; 22 (14) 2877-2884
• 6 Tekautz TM, Fuller CE, Blaney S , et al. Atypical teratoid/rhabdoid tumors (ATRT): improved survival in children 3 years of age and older with radiation therapy and high-dose alkylator-based chemotherapy. J Clin Oncol 2005; 23 (7) 1491-1499
• 7 Benesch M, Bartelheim K, Fleischhack G , et al. High-dose chemotherapy (HDCT) with auto-SCT in children with atypical teratoid/rhabdoid tumors (AT/RT): a report from the European Rhabdoid Registry (EU-RHAB). Bone Marrow Transplant 2014; 49 (3) 370-375
• 8 Zaky W, Dhall G, Ji L , et al. Intensive induction chemotherapy followed by myeloablative chemotherapy with autologous hematopoietic progenitor cell rescue for young children newly-diagnosed with central nervous system atypical teratoid/rhabdoid tumors: the Head Start III experience. Pediatr Blood Cancer 2014; 61 (1) 95-101
• 9 Hochstrasser H, Boltshauser E, Valavanis A. Brain tumors in children with von Recklinghausen neurofibromatosis. Neurofibromatosis 1988; 1 (4) 233-239
• 10 Kuenzle C, Weissert M, Roulet E , et al. Follow-up of optic pathway gliomas in children with neurofibromatosis type 1. Neuropediatrics 1994; 25 (6) 295-300
• 11 Janss AJ, Grundy R, Cnaan A , et al. Optic pathway and hypothalamic/chiasmatic gliomas in children younger than age 5 years with a 6-year follow-up. Cancer 1995; 75 (4) 1051-1059
• 12 El Kababri M, André N, Carole C, Lena G, Figarella-Branger D, Gentet JC. Atypical teratoid rhabdoid tumor in a child with neurofibromatosis 1. Pediatr Blood Cancer 2006; 46 (2) 267-268
• 13 Relling MV, Rubnitz JE, Rivera GK , et al. High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet 1999; 354 (9172) 34-39
• 14 Uchino Y, Saeki N, Iwadate Y , et al. Recurrence of sellar and suprasellar tumors in children treated with hGH—relation to immunohistochemical study on GH receptor. Endocr J 2000; 47: S33-S36
• 15 Wilson TA, Rose SR, Cohen P , et al; Lawson Wilkins Pediatric Endocrinology Society Drug and Therapeutics Committee. Update of guidelines for the use of growth hormone in children: the Lawson Wilkins Pediatric Endocrinology Society Drug and Therapeutics Committee. J Pediatr 2003; 143 (4) 415-421
• 16 Gleeson HK, Shalet SM. Evaluation and Management of Late Effects of Cancer Treatment. In: Brook CGD, Clayton PE, Brown RS, , eds. Clinical Paediatric Endocrinology. 6th ed. Wiley-Blackwell, 2009: 169-185
• 17 Howell SJ, Wilton P, Lindberg A, Shalet SM. Growth hormone replacement and the risk of malignancy in children with neurofibromatosis. J Pediatr 1998; 133 (2) 201-205